Long-term study of a quadrivalent human papillomavirus vaccine

Pediatrics

Volumn 134, Issue 3, 2014, Pages e657-e665

  Ferris, Daron ^a   Samakoses, Rudiwilai ^b   Block, Stan L ^c   Lazcano Ponce, Eduardo ^d   Alberto Restrepo, Jaime ^e   Reisinger, Keith S ^f   Mehlsen, Jesper ^g   Chatterjee, Archana ^h   Iversen, Ole Erik ⁱ   Sings, Heather L ^j   Shou, Qiong ^j   Sausser, Timothy A ^j   Saah, Alfred ^j  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b PHRAMONGKUTKLAO HOSPITAL   (Thailand)

^c Kentucky Pediatric Research Institute   (United States)

^d INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^e Research Center   (Colombia)

^f Primary Physicians Research   (United States)

^g FREDERIKSBERG HOSPITAL   (Denmark)

^h UNIVERSITY OF SOUTH DAKOTA   (United States)

ⁱ HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^j MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

Adolescents; Anogenital cancer; Effectiveness; Genital warts; Immunogenicity; Quadrivalent HPV vaccine; Safety

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

ABSENCE OF SIDE EFFECTS; ACCIDENTAL INJURY; ADOLESCENT; ANTIBODY RESPONSE; ARTICLE; BLOOD LEVEL; CHILD; CHOANA ATRESIA; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONGENITAL MALFORMATION; CONTROLLED STUDY; CRANIAL NERVE PARALYSIS; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; LONG TERM CARE; MALE; NONHUMAN; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; SCHOOL CHILD; TONIC CLONIC SEIZURE; TREATMENT DURATION; VACCINATION; VACCINATION REACTION; VIRUS IDENTIFICATION; ADOLESCENTS; ANOGENITAL CANCER; BLOOD; CONDYLOMA ACUMINATUM; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EFFICACY; MULTICENTER STUDY; PHYSIOLOGY; QUADRIVALENT HPV VACCINE; RANDOMIZED CONTROLLED TRIAL; SAFETY; TIME; TREATMENT OUTCOME;

ADOLESCENTS; ANOGENITAL CANCER; EFFECTIVENESS; GENITAL WARTS; IMMUNOGENICITY; QUADRIVALENT HPV VACCINE; SAFETY;

ADOLESCENT; CHILD; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMAN PAPILLOMAVIRUS 6; HUMANS; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TIME FACTORS; TREATMENT OUTCOME; VACCINATION;

EID: 84907208597     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2013-4144     Document Type: Article

References (29)

1. Garland SM, Hernandez-Avila M, Wheeler CM, et al; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928-1943
2. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915-1927
3. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011;364(5):401-411
4. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365(17):1576-1585
5. Block SL, Nolan T, Sattler C, et al; Protocol 016 Study Group. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006;118(5): 2135-2145
6. Reisinger KS, Block SL, Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J. 2007;26(3):201-209
7. Muñoz N, Manalastas R, Pitisuttihum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in adult women between 24 and 45 years of age: a randomised, double-blind trial. Lancet. 2009;373(9679):1949-1957
8. Giuliano A, Lazcano-Ponce E, Villa L, et al. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine. J Infect Dis. 2007;196(8):1153-1162
9. Olsson S-E, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/ 16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007;25(26):4931-4939
10. Block SL, Brown DR, Chatterjee A, et al. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 viruslike particle vaccine. Pediatr Infect Dis J. 2010;29(2):95-101
11. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009;302(7):750-757
12. Gee J, Naleway A, Shui I, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine. 2011;29(46):8279-8284
13. Australian Government Department of Heath and Ageing TGA. Gardasil (human papillomavirus vaccine). Available at: http://www.tga.gov.au/safety/alerts-medicine-gardasil-070624.htm. Accessed August 14, 2013
14. Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis. 2013;208(3):385-393
15. Brotherton J, Fridman M, Saville M, Gertig D. First indication of a possible impact on cervical abnormalities following a national HPV vaccination program in Victoria, Australia. Updated July 2010. Abstract # 508, presented at IPV 2010, Montreal. Available at www.hpv2010.org/main/index.php?option=com-conference&view=presentation&id=1746&conference=1&Itemid=103. Accessed July 15, 2014
16. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet. 2011;377(9783):2085-2092
17. Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013;346f2032
18. Ali H, Guy RJ, Wand H, et al. Decline in inpatient treatments of genital warts among young Australians following the national HPV vaccination program. BMC Infect Dis. 2013;13:140
19. Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis. 2011;11(1):39-44
20. Centers for Disease Control and Prevention. HPV vaccine: safe, effective, and grossly underutilized. Available at: http://www.cdc.gov/media/releases/2013/p0725-HPVvaccine.html. Accessed August 14, 2013
21. Brown DR, Garland SM, Ferris DG, et al. The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay. Hum Vaccin. 2011;7(2):230-238
22. Opalka D, Lachman CE, MacMullen SA, et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol. 2003;10(1):108-115
23. Opalka D, Matys K, Bojczuk P, et al. Multiplexed serologic assay for nine anogenital human papillomavirus types. Clin Vaccine Immunol. 2010;17(5):818-827
24. Joura EA, Kjaer SK, Wheeler CM, et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine. 2008;26 (52):6844-6851
25. Bauer HM, Wright G, Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-2010. Am J Public Health. 2012;102(5):833-835
26. Nsouli-Maktabi H, Ludwig SL, Yerubandi UD, Gaydos JC. Incidence of genital warts among U.S. service members before and after the introduction of the quadrivalent human papillomavirus vaccine. MSMR. 2013;20(2):17-20
27. Leval A, Herweijer E, Arnheim-Dahlström L, et al. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis. 2012;206(6):860-866
28. Baandrup L, Blomberg M, Dehlendorff C, Sand C, Andersen KK, Kjaer SK. Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis. 2013;40(2):130-135
29. Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK. Early impact of human papillomavirus vaccination on cervical neoplasia - Nationwide Follow-up of Young Danish Women. J Natl Cancer Inst. 2014. Available at http://jnci.oxfordjournals.org/content/early/2014/02/19/jnci.djt460.short. Accessed July 1, 2014